Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$2.00 -0.5%	$1.97	$0.77 ▼ $4.08	$276.57M	1.4	907,126 shs	1.10 million shs
CNTX Context Therapeutics	$0.82 +5.1%	$0.78	$0.55 ▼ $2.75	$73.56M	2.11	292,141 shs	143,109 shs
CRVS Corvus Pharmaceuticals	$3.89 -4.0%	$3.61	$1.75 ▼ $10.00	$265.18M	0.67	711,113 shs	852,330 shs
DBVT DBV Technologies	$10.99 +8.5%	$7.02	$2.20 ▼ $11.19	$301.02M	-0.66	186,628 shs	107,957 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	+10.44%	+8.06%	+18.58%	-44.93%	+25.63%
CNTX Context Therapeutics	+2.42%	-7.01%	-0.03%	-0.35%	-58.29%
CRVS Corvus Pharmaceuticals	-8.58%	+13.45%	+35.91%	-18.35%	+94.71%
DBVT DBV Technologies	+3.05%	+9.51%	+38.39%	+141.77%	+75.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPX Compass Therapeutics	3.3709 of 5 stars	4.6	1.0	2.4	5.0	0.0
CNTX Context Therapeutics	1.8348 of 5 stars	3.6	2.0	2.5	0.0	0.6
CRVS Corvus Pharmaceuticals	2.3373 of 5 stars	3.6	1.0	2.7	2.5	0.6
DBVT DBV Technologies	3.2935 of 5 stars	3.5	5.0	3.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPX Compass Therapeutics	3.11	Buy	$13.13	556.25% Upside
CNTX Context Therapeutics	3.14	Buy	$5.40	558.54% Upside
CRVS Corvus Pharmaceuticals	3.25	Buy	$16.33	319.88% Upside
DBVT DBV Technologies	3.00	Buy	$15.50	41.04% Upside

Current Analyst Ratings Breakdown

Latest CNTX, CMPX, DBVT, and CRVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
5/9/2025	CRVS Corvus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$15.00 ➝ $17.00
5/8/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
5/5/2025	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $16.00
5/1/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $15.00
4/29/2025	CNTX Context Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/29/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/28/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/22/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/21/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
4/21/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00

(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPX Compass Therapeutics	$850K	325.37	N/A	N/A	$1.17 per share	1.71
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$0.74 per share	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$0.79 per share	N/A
DBVT DBV Technologies	$15.73M	19.14	N/A	N/A	$7.27 per share	1.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPX Compass Therapeutics	-$42.49M	-$0.41	N/A	N/A	N/A	N/A	-32.37%	-30.67%	N/A
CNTX Context Therapeutics	-$23.96M	-$0.31	N/A	N/A	N/A	N/A	-58.76%	-55.80%	5/14/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$27.03M	-$0.98	N/A	N/A	N/A	N/A	-70.71%	-45.90%	N/A
DBVT DBV Technologies	-$72.73M	-$4.92	N/A	N/A	N/A	-815.73%	-106.07%	-76.17%	7/29/2025 (Estimated)

Latest CNTX, CMPX, DBVT, and CRVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	CNTX Context Therapeutics	-$0.05	-$0.05	N/A	-$0.05	N/A	N/A
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
5/8/2025	Q1 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.13	N/A	-$0.13	N/A	N/A
4/11/2025	Q4 2024	DBVT DBV Technologies	N/A	-$1.10	N/A	-$1.10	N/A	$0.51 million
3/25/2025	Q4 2024	CRVS Corvus Pharmaceuticals	-$0.12	-$0.18	-$0.06	-$0.18	N/A	N/A
3/20/2025	Q4 2024	CNTX Context Therapeutics	-$0.05	-$0.04	+$0.01	N/A	N/A	N/A
2/27/2025	Q4 2024	CMPX Compass Therapeutics	-$0.10	-$0.11	-$0.01	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPX Compass Therapeutics	N/A	31.84	31.84
CNTX Context Therapeutics	N/A	36.91	36.91
CRVS Corvus Pharmaceuticals	N/A	0.92	0.92
DBVT DBV Technologies	N/A	2.22	2.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPX Compass Therapeutics	68.43%
CNTX Context Therapeutics	14.03%
CRVS Corvus Pharmaceuticals	46.64%
DBVT DBV Technologies	71.74%

Insider Ownership

Company	Insider Ownership
CMPX Compass Therapeutics	28.50%
CNTX Context Therapeutics	2.80%
CRVS Corvus Pharmaceuticals	28.50%
DBVT DBV Technologies	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPX Compass Therapeutics	20	138.28 million	98.38 million	Not Optionable
CNTX Context Therapeutics	7	89.70 million	72.72 million	Not Optionable
CRVS Corvus Pharmaceuticals	30	68.17 million	44.15 million	Optionable
DBVT DBV Technologies	80	27.39 million	20.18 million	Optionable

CNTX, CMPX, DBVT, and CRVS Headlines

Recent News About These Companies

DBV Technologies (NASDAQ:DBVT) Rating Increased to Hold at StockNews.com

May 11 at 4:13 AM | marketbeat.com

DBV Technologies (NASDAQ:DBVT) Upgraded at StockNews.com

May 11 at 2:01 AM | americanbankingnews.com

HC Wainwright Has Bullish Estimate for DBVT FY2025 Earnings

May 10 at 8:54 AM | marketbeat.com

HC Wainwright Has Positive Outlook of DBVT FY2026 Earnings

May 9, 2025 | marketbeat.com

HC Wainwright Has Positive Outlook for DBVT FY2026 Earnings

May 9, 2025 | americanbankingnews.com

What is HC Wainwright's Estimate for DBVT FY2025 Earnings?

May 9, 2025 | americanbankingnews.com

What is HC Wainwright's Estimate for DBVT Q2 Earnings?

May 8, 2025 | marketbeat.com

What is HC Wainwright's Forecast for DBVT Q2 Earnings?

May 8, 2025 | americanbankingnews.com

DBV Technologies (NASDAQ:DBVT) Given New $16.00 Price Target at HC Wainwright

May 7, 2025 | marketbeat.com

Baker BROS. Advisors LP Has $4.52 Million Holdings in DBV Technologies S.A. (NASDAQ:DBVT)

May 6, 2025 | marketbeat.com

DBV Technologies to Participate in the Citizens JMP Life Sciences Conference

May 5, 2025 | globenewswire.com

DBV Technologies (NASDAQ:DBVT) Share Price Passes Above 50-Day Moving Average - Should You Sell?

May 4, 2025 | marketbeat.com

50,000 Shares in DBV Technologies S.A. (NASDAQ:DBVT) Acquired by Boxer Capital Management LLC

May 4, 2025 | marketbeat.com

DBV Technologies (NASDAQ:DBVT) Price Target Raised to $15.00

May 3, 2025 | americanbankingnews.com

DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

May 3, 2025 | marketbeat.com

DBV Technologies S.A.: DBV Technologies Reports First Quarter 2025 Financial Results

May 1, 2025 | finanznachrichten.de

DBV Technologies Reports First Quarter 2025 Financial Results

April 30, 2025 | globenewswire.com

Here's Why Momentum in DBV Technologies (DBVT) Should Keep going

April 30, 2025 | zacks.com

Why DBV Technologies S.A. (DBVT) is Surging in 2025

April 30, 2025 | insidermonkey.com

DBV Technologies S.A. (NASDAQ:DBVT) Short Interest Down 71.2% in April

April 29, 2025 | marketbeat.com

StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)

April 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX, CMPX, DBVT, and CRVS Company Descriptions

Compass Therapeutics NASDAQ:CMPX

$2.00 -0.01 (-0.50%)

As of 04:00 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Context Therapeutics NASDAQ:CNTX

$0.82 +0.04 (+5.14%)

As of 04:00 PM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Corvus Pharmaceuticals NASDAQ:CRVS

$3.89 -0.16 (-3.95%)

As of 04:00 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

DBV Technologies NASDAQ:DBVT

$10.99 +0.86 (+8.49%)

As of 04:00 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time